- Isis Pharmaceuticals (ISIS) changed its name to Ionis Pharmaceuticals (IONS) (Dec 2015)
ISIS Pharm reports positive clinical data from Lp(a) lowering drugs :
Co announced positive results from a Phase 2 study of ISIS-APO(a)Rx in which patients with high lipoprotein(a), or Lp(a), achieved reductions in Lp(a) of up to 94%, with a mean reduction of 71 percent.
- Lp(a) is a known driver of cardiovascular disease.
- They also announced results from a Phase 1/2a study of ISIS-APO(a)-LRx in which subjects with elevated Lp(a) achieved dose-dependent reductions in Lp(a) of up to 99 percent.
- ISIS-APO(a)-LRx is a LIgand Conjugated Antisense (:LICA) version of ISIS-APO(a)Rx. ISIS-APO(a)-LRx demonstrated a greater than 30-fold increase in potency in humans as compared to ISIS-APO(a)